drugset / Trial / NCT01907867

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

NCT01907867

Phase 1 Completed 18 enrolled MerLion Pharmaceuticals GmbH
Non-randomizedCrossoverOpen-labelTreatment

Summary

This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted.

Timeline

Start
2012-01
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Finafloxacin Small molecule 800 mg Oral

Indications

No indication recorded.